Market Analysis and Insights: Global Nucleic Acid-based Drugs Market
The global Nucleic Acid-based Drugs market is projected to grow from US$ million in 2023 to US$ million by 2029, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
The US & Canada market for Nucleic Acid-based Drugs is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The China market for Nucleic Acid-based Drugs is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The Europe market for Nucleic Acid-based Drugs is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The global key companies of Nucleic Acid-based Drugs include Ionis Pharmaceuticals, Sarepta Therapeutics, Nippon Shinyaku, BioNTech, Moderna Therapeutics, CureVac, Alnylam Pharmaceuticals, Regulus Therapeutics and Miragen Therapeutics, etc. in 2022, the global top five players had a share approximately % in terms of revenue.
Report Includes
This report presents an overview of global market for Nucleic Acid-based Drugs market size. Analyses of the global market trends, with historic market revenue data for 2018 - 2022, estimates for 2023, and projections of CAGR through 2029.
This report researches the key producers of Nucleic Acid-based Drugs, also provides the revenue of main regions and countries. Highlights of the upcoming market potential for Nucleic Acid-based Drugs, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Nucleic Acid-based Drugs revenue, market share and industry ranking of main companies, data from 2018 to 2023. Identification of the major stakeholders in the global Nucleic Acid-based Drugs market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by type and by application, revenue, and growth rate, from 2018 to 2029. Evaluation and forecast the market size for Nucleic Acid-based Drugs revenue, projected growth trends, production technology, application and end-user industry.
Descriptive company profiles of the major global players, including Ionis Pharmaceuticals, Sarepta Therapeutics, Nippon Shinyaku, BioNTech, Moderna Therapeutics, CureVac, Alnylam Pharmaceuticals, Regulus Therapeutics and Miragen Therapeutics, etc.
By Company
Ionis Pharmaceuticals
Sarepta Therapeutics
Nippon Shinyaku
BioNTech
Moderna Therapeutics
CureVac
Alnylam Pharmaceuticals
Regulus Therapeutics
Miragen Therapeutics
Mina Therapeutics
NeXstar Pharmaceuticals
Segment by Type
ASO
mRNA
siRNA
miRNA
saRNA
Aptamer
Segment by Application
Genetic Disease
Cancer
Cardiovascular Diseases
Other
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East, Africa, and Latin America
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Revenue of Nucleic Acid-based Drugs in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Nucleic Acid-based Drugs companies鈥� competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: North America by type, by application and by country, revenue for each segment.
Chapter 7: Europe by type, by application and by country, revenue for each segment.
Chapter 8: China by type and by application revenue for each segment.
Chapter 9: Asia (excluding China) by type, by application and by region, revenue for each segment.
Chapter 10: Middle East, Africa, and Latin America by type, by application and by country, revenue for each segment.
Chapter 11: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Nucleic Acid-based Drugs revenue, gross margin, and recent development, etc.
Chapter 12: Analyst's Viewpoints/Conclusions
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Nucleic Acid-based Drugs Market Size Growth Rate by Type, 2018 VS 2022 VS 2029
1.2.2 ASO
1.2.3 mRNA
1.2.4 siRNA
1.2.5 miRNA
1.2.6 saRNA
1.2.7 Aptamer
1.3 Market by Application
1.3.1 Global Nucleic Acid-based Drugs Market Size Growth Rate by Application, 2018 VS 2022 VS 2029
1.3.2 Genetic Disease
1.3.3 Cancer
1.3.4 Cardiovascular Diseases
1.3.5 Other
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Nucleic Acid-based Drugs Market Perspective (2018-2029)
2.2 Global Nucleic Acid-based Drugs Growth Trends by Region
2.2.1 Nucleic Acid-based Drugs Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Nucleic Acid-based Drugs Historic Market Size by Region (2018-2023)
2.2.3 Nucleic Acid-based Drugs Forecasted Market Size by Region (2024-2029)
2.3 Nucleic Acid-based Drugs Market Dynamics
2.3.1 Nucleic Acid-based Drugs Industry Trends
2.3.2 Nucleic Acid-based Drugs Market Drivers
2.3.3 Nucleic Acid-based Drugs Market Challenges
2.3.4 Nucleic Acid-based Drugs Market Restraints
3 Competition Landscape by Key Players
3.1 Global Revenue Nucleic Acid-based Drugs by Players
3.1.1 Global Nucleic Acid-based Drugs Revenue by Players (2018-2023)
3.1.2 Global Nucleic Acid-based Drugs Revenue Market Share by Players (2018-2023)
3.2 Global Nucleic Acid-based Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players of Nucleic Acid-based Drugs, Ranking by Revenue, 2021 VS 2022 VS 2023
3.4 Global Nucleic Acid-based Drugs Market Concentration Ratio
3.4.1 Global Nucleic Acid-based Drugs Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Nucleic Acid-based Drugs Revenue in 2022
3.5 Global Key Players of Nucleic Acid-based Drugs Head office and Area Served
3.6 Global Key Players of Nucleic Acid-based Drugs, Product and Application
3.7 Global Key Players of Nucleic Acid-based Drugs, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Nucleic Acid-based Drugs Breakdown Data by Type
4.1 Global Nucleic Acid-based Drugs Historic Market Size by Type (2018-2023)
4.2 Global Nucleic Acid-based Drugs Forecasted Market Size by Type (2024-2029)
5 Nucleic Acid-based Drugs Breakdown Data by Application
5.1 Global Nucleic Acid-based Drugs Historic Market Size by Application (2018-2023)
5.2 Global Nucleic Acid-based Drugs Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America Nucleic Acid-based Drugs Market Size (2018-2029)
6.2 North America Nucleic Acid-based Drugs Market Size by Type
6.2.1 North America Nucleic Acid-based Drugs Market Size by Type (2018-2023)
6.2.2 North America Nucleic Acid-based Drugs Market Size by Type (2024-2029)
6.2.3 North America Nucleic Acid-based Drugs Market Share by Type (2018-2029)
6.3 North America Nucleic Acid-based Drugs Market Size by Application
6.3.1 North America Nucleic Acid-based Drugs Market Size by Application (2018-2023)
6.3.2 North America Nucleic Acid-based Drugs Market Size by Application (2024-2029)
6.3.3 North America Nucleic Acid-based Drugs Market Share by Application (2018-2029)
6.4 North America Nucleic Acid-based Drugs Market Size by Country
6.4.1 North America Nucleic Acid-based Drugs Market Size by Country: 2018 VS 2022 VS 2029
6.4.2 North America Nucleic Acid-based Drugs Market Size by Country (2018-2023)
6.4.3 North America Nucleic Acid-based Drugs Market Size by Country (2024-2029)
6.4.4 United States
6.4.5 Canada
7 Europe
7.1 Europe Nucleic Acid-based Drugs Market Size (2018-2029)
7.2 Europe Nucleic Acid-based Drugs Market Size by Type
7.2.1 Europe Nucleic Acid-based Drugs Market Size by Type (2018-2023)
7.2.2 Europe Nucleic Acid-based Drugs Market Size by Type (2024-2029)
7.2.3 Europe Nucleic Acid-based Drugs Market Share by Type (2018-2029)
7.3 Europe Nucleic Acid-based Drugs Market Size by Application
7.3.1 Europe Nucleic Acid-based Drugs Market Size by Application (2018-2023)
7.3.2 Europe Nucleic Acid-based Drugs Market Size by Application (2024-2029)
7.3.3 Europe Nucleic Acid-based Drugs Market Share by Application (2018-2029)
7.4 Europe Nucleic Acid-based Drugs Market Size by Country
7.4.1 Europe Nucleic Acid-based Drugs Market Size by Country: 2018 VS 2022 VS 2029
7.4.2 Europe Nucleic Acid-based Drugs Market Size by Country (2018-2023)
7.4.3 Europe Nucleic Acid-based Drugs Market Size by Country (2024-2029)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries
8 China
8.1 China Nucleic Acid-based Drugs Market Size (2018-2029)
8.2 China Nucleic Acid-based Drugs Market Size by Type
8.2.1 China Nucleic Acid-based Drugs Market Size by Type (2018-2023)
8.2.2 China Nucleic Acid-based Drugs Market Size by Type (2024-2029)
8.2.3 China Nucleic Acid-based Drugs Market Share by Type (2018-2029)
8.3 China Nucleic Acid-based Drugs Market Size by Application
8.3.1 China Nucleic Acid-based Drugs Market Size by Application (2018-2023)
8.3.2 China Nucleic Acid-based Drugs Market Size by Application (2024-2029)
8.3.3 China Nucleic Acid-based Drugs Market Share by Application (2018-2029)
9 Asia (excluding China)
9.1 Asia Nucleic Acid-based Drugs Market Size (2018-2029)
9.2 Asia Nucleic Acid-based Drugs Market Size by Type
9.2.1 Asia Nucleic Acid-based Drugs Market Size by Type (2018-2023)
9.2.2 Asia Nucleic Acid-based Drugs Market Size by Type (2024-2029)
9.2.3 Asia Nucleic Acid-based Drugs Market Share by Type (2018-2029)
9.3 Asia Nucleic Acid-based Drugs Market Size by Application
9.3.1 Asia Nucleic Acid-based Drugs Market Size by Application (2018-2023)
9.3.2 Asia Nucleic Acid-based Drugs Market Size by Application (2024-2029)
9.3.3 Asia Nucleic Acid-based Drugs Market Share by Application (2018-2029)
9.4 Asia Nucleic Acid-based Drugs Market Size by Region
9.4.1 Asia Nucleic Acid-based Drugs Market Size by Region: 2018 VS 2022 VS 2029
9.4.2 Asia Nucleic Acid-based Drugs Market Size by Region (2018-2023)
9.4.3 Asia Nucleic Acid-based Drugs Market Size by Region (2024-2029)
9.4.4 Japan
9.4.5 South Korea
9.4.6 China Taiwan
9.4.7 Southeast Asia
9.4.8 India
9.4.9 Australia
10 Middle East, Africa, and Latin America
10.1 Middle East, Africa, and Latin America Nucleic Acid-based Drugs Market Size (2018-2029)
10.2 Middle East, Africa, and Latin America Nucleic Acid-based Drugs Market Size by Type
10.2.1 Middle East, Africa, and Latin America Nucleic Acid-based Drugs Market Size by Type (2018-2023)
10.2.2 Middle East, Africa, and Latin America Nucleic Acid-based Drugs Market Size by Type (2024-2029)
10.2.3 Middle East, Africa, and Latin America Nucleic Acid-based Drugs Market Share by Type (2018-2029)
10.3 Middle East, Africa, and Latin America Nucleic Acid-based Drugs Market Size by Application
10.3.1 Middle East, Africa, and Latin America Nucleic Acid-based Drugs Market Size by Application (2018-2023)
10.3.2 Middle East, Africa, and Latin America Nucleic Acid-based Drugs Market Size by Application (2024-2029)
10.3.3 Middle East, Africa, and Latin America Nucleic Acid-based Drugs Market Share by Application (2018-2029)
10.4 Middle East, Africa, and Latin America Nucleic Acid-based Drugs Market Size by Country
10.4.1 Middle East, Africa, and Latin America Nucleic Acid-based Drugs Market Size by Country: 2018 VS 2022 VS 2029
10.4.2 Middle East, Africa, and Latin America Nucleic Acid-based Drugs Market Size by Country (2018-2023)
10.4.3 Middle East, Africa, and Latin America Nucleic Acid-based Drugs Market Size by Country (2024-2029)
10.4.4 Brazil
10.4.5 Mexico
10.4.6 Turkey
10.4.7 Saudi Arabia
10.4.8 Israel
10.4.9 GCC Countries
11 Key Players Profiles
11.1 Ionis Pharmaceuticals
11.1.1 Ionis Pharmaceuticals Company Details
11.1.2 Ionis Pharmaceuticals Business Overview
11.1.3 Ionis Pharmaceuticals Nucleic Acid-based Drugs Introduction
11.1.4 Ionis Pharmaceuticals Revenue in Nucleic Acid-based Drugs Business (2018-2023)
11.1.5 Ionis Pharmaceuticals Recent Developments
11.2 Sarepta Therapeutics
11.2.1 Sarepta Therapeutics Company Details
11.2.2 Sarepta Therapeutics Business Overview
11.2.3 Sarepta Therapeutics Nucleic Acid-based Drugs Introduction
11.2.4 Sarepta Therapeutics Revenue in Nucleic Acid-based Drugs Business (2018-2023)
11.2.5 Sarepta Therapeutics Recent Developments
11.3 Nippon Shinyaku
11.3.1 Nippon Shinyaku Company Details
11.3.2 Nippon Shinyaku Business Overview
11.3.3 Nippon Shinyaku Nucleic Acid-based Drugs Introduction
11.3.4 Nippon Shinyaku Revenue in Nucleic Acid-based Drugs Business (2018-2023)
11.3.5 Nippon Shinyaku Recent Developments
11.4 BioNTech
11.4.1 BioNTech Company Details
11.4.2 BioNTech Business Overview
11.4.3 BioNTech Nucleic Acid-based Drugs Introduction
11.4.4 BioNTech Revenue in Nucleic Acid-based Drugs Business (2018-2023)
11.4.5 BioNTech Recent Developments
11.5 Moderna Therapeutics
11.5.1 Moderna Therapeutics Company Details
11.5.2 Moderna Therapeutics Business Overview
11.5.3 Moderna Therapeutics Nucleic Acid-based Drugs Introduction
11.5.4 Moderna Therapeutics Revenue in Nucleic Acid-based Drugs Business (2018-2023)
11.5.5 Moderna Therapeutics Recent Developments
11.6 CureVac
11.6.1 CureVac Company Details
11.6.2 CureVac Business Overview
11.6.3 CureVac Nucleic Acid-based Drugs Introduction
11.6.4 CureVac Revenue in Nucleic Acid-based Drugs Business (2018-2023)
11.6.5 CureVac Recent Developments
11.7 Alnylam Pharmaceuticals
11.7.1 Alnylam Pharmaceuticals Company Details
11.7.2 Alnylam Pharmaceuticals Business Overview
11.7.3 Alnylam Pharmaceuticals Nucleic Acid-based Drugs Introduction
11.7.4 Alnylam Pharmaceuticals Revenue in Nucleic Acid-based Drugs Business (2018-2023)
11.7.5 Alnylam Pharmaceuticals Recent Developments
11.8 Regulus Therapeutics
11.8.1 Regulus Therapeutics Company Details
11.8.2 Regulus Therapeutics Business Overview
11.8.3 Regulus Therapeutics Nucleic Acid-based Drugs Introduction
11.8.4 Regulus Therapeutics Revenue in Nucleic Acid-based Drugs Business (2018-2023)
11.8.5 Regulus Therapeutics Recent Developments
11.9 Miragen Therapeutics
11.9.1 Miragen Therapeutics Company Details
11.9.2 Miragen Therapeutics Business Overview
11.9.3 Miragen Therapeutics Nucleic Acid-based Drugs Introduction
11.9.4 Miragen Therapeutics Revenue in Nucleic Acid-based Drugs Business (2018-2023)
11.9.5 Miragen Therapeutics Recent Developments
11.10 Mina Therapeutics
11.10.1 Mina Therapeutics Company Details
11.10.2 Mina Therapeutics Business Overview
11.10.3 Mina Therapeutics Nucleic Acid-based Drugs Introduction
11.10.4 Mina Therapeutics Revenue in Nucleic Acid-based Drugs Business (2018-2023)
11.10.5 Mina Therapeutics Recent Developments
11.11 NeXstar Pharmaceuticals
11.11.1 NeXstar Pharmaceuticals Company Details
11.11.2 NeXstar Pharmaceuticals Business Overview
11.11.3 NeXstar Pharmaceuticals Nucleic Acid-based Drugs Introduction
11.11.4 NeXstar Pharmaceuticals Revenue in Nucleic Acid-based Drugs Business (2018-2023)
11.11.5 NeXstar Pharmaceuticals Recent Developments
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Ionis Pharmaceuticals
Sarepta Therapeutics
Nippon Shinyaku
BioNTech
Moderna Therapeutics
CureVac
Alnylam Pharmaceuticals
Regulus Therapeutics
Miragen Therapeutics
Mina Therapeutics
NeXstar Pharmaceuticals
听
听
*If Applicable.
